

INDICATION

ABRYSVO® is a vaccine indicated for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in people 60 years of age and older.

IMPORTANT SAFETY INFORMATION

 ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components

RSV is a highly contagious virus that can have severe symptoms.

Respiratory syncytial virus (RSV) is a virus that affects the lungs and airways, and spreads easily. With symptoms similar to the flu, it can range from mild to severe, potentially leading to difficulties in breathing.



RSV can start mild, like a cold, with symptoms like congestion, runny nose, sore throat, fever, and cough. But it can quickly become serious, with symptoms like:

- difficulty breathing
- wheezing
- wet cough
- pneumonia

IMPORTANT SAFETY INFORMATION (continued)

 An increased risk of Guillain-Barré syndrome (severe muscle weakness) was observed after vaccination with ABRYSVO

RSV can be very serious.



As you age, your immune system weakens, potentially leaving you vulnerable to serious infections, like RSV.



- Are you 75 or older?
- Are you 60 or older with a chronic condition like asthma, COPD, heart disease or diabetes?

RSV can make you very sick and there are no prescription RSV treatments available for adults.



In very serious cases, RSV can lead to hospitalization and death.

IMPORTANT SAFETY INFORMATION (continued)

- Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
- Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO
- Vaccination with ABRYSVO may not protect all people
- In adults 60 years of age and older, the most common side effects (≥10%) were fatigue, headache, pain at the injection site, and muscle pain



ABRYSVO is proven to help protect against RSV.

The CDC recommends a single dose of ABRYSVO for adults 75+ and those 60 or older with certain chronic conditions like asthma, COPD, heart disease and diabetes.

ABRYSVO (Respiratory Syncytial Virus Vaccine) helps your immune system make antibodies against RSV, so your body is better prepared to help protect you from the virus.

ABRYSVO was studied in a large clinical trial of 34,000 adults 60 and older, where half received ABRYSVO and half received placebo. Pfizer's RSV vaccine ABRYSVO was proven effective against RSV.

The most common side effects of participants who received ABRYSVO were fatigue, headache, pain at the injection site, and muscle pain. 9 out of 10 adults who received ABRYSVO in the clinical trial reported no injection-site side effects.



If you are 60 years of age or older and remain unvaccinated, talk to your pharmacist or doctor to see if ABRYSVO is right for you.

For more information, or to find ABRYSVO at a pharmacy or doctor near you, visit

www.abrysvo.com



Use your smartphone camera to scan to find where to get **ABRYSVO** near you.



IMPORTANT SAFETY INFORMATION (continued)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

Cost and coverage*

Pfizer's ABRYSVO may be made available at no cost in accordance with the Inflation Reduction Act.*

Talk to your doctor or pharmacist to see if Pfizer's ABRYSVO is covered under your insurance plan. Additional savings and support options may be available at Pfizer RxPathways[®].

*This information is provided for informational purposes only.

Accurate completion of reimbursement or coverage-related documentation is the responsibility of the healthcare provider and patient. Pfizer and its agents make no guarantee regarding reimbursement for any service or item.



You are encouraged to report side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see Important Safety Information on pages 1-6.
Please click for full <u>Prescribing Information for ABRYSVO</u>.

PP-A1G-USA-2077 © 2025 Pfizer Inc. All rights reserved. February 2025